What Retacrit Treats: Main Uses and Benefits

Retacrit (epoetin alfa-epbx) is applied across domains where additional symptomatic support is needed by addressing challenges related to anemia associated with certain clinical situations. Its core therapeutic benefit is to offer support across symptom-focused domains where insufficient red blood cells cause noticeable discomfort and functional strain.

The primary clinical contexts for its use include anemia associated with Chronic Kidney Disease (CKD), certain chemotherapy regimens, HIV treatment, and for helping reduce the need for RBC transfusions in specific surgical patients.

Chronic Symptom Management and Supportive Care

The medication is relevant in contexts marked by increased discomfort or tension due to anemia from chronic conditions. Retacrit is used during phases when symptoms become more noticeable and symptoms lead to temporary functional strain. It is relevant for easing symptoms related to physical discomfort, which provides support that helps ease the overall symptom burden.

“This medication is applied across domains where additional symptomatic support is needed.”

Quick Support for Systemic Symptoms: Retacrit is relevant for easing symptoms related to systemic imbalance, which supports general well-being during symptomatic phases.

Retacrit eligibility is defined by absolute contraindications and specific patient characteristics detailed in official regulatory labels.

Populations for Whom Use is Contraindicated

Retacrit must not be used in patients with:

• Uncontrolled hypertension (high blood pressure).
• A history of Pure Red Cell Aplasia (PRCA) following prior treatment with any erythropoietin protein drug.
• Known serious allergic reactions or hypersensitivity to the drug or its components.
• Neonates, infants, pregnant women, and lactating women are contraindicated for use of the multiple-dose vial formulation due to the benzyl alcohol preservative.

Age-Related and Condition-Specific Rules

Retacrit is approved for adults across all indications, and for pediatric patients (as young as one month) with anemia associated with Chronic Kidney Disease (CKD). Use of the multiple-dose vial is strictly prohibited in infants and pregnant/lactating women; only benzyl alcohol-free single-dose vials must be used. Caution is required in patients with a history of epilepsy or chronic liver failure. Furthermore, the medicine is not indicated for cancer patients when the anticipated outcome of chemotherapy is cure or for patients undergoing cardiac or vascular surgery.

The official interaction profile for Retacrit (epoetin alfa-epbx), a large recombinant protein and an Erythropoiesis-Stimulating Agent, is primarily defined by specific substance restrictions related to its formulation and by the patient's required nutritional status, rather than interactions with other medicines.

Regulatory Constraints:

The contraindication related to Benzyl Alcohol is strictly limited to the multiple-dose vial formulation and is applied as a necessary population-dependent restriction. Additionally, the single-dose vial contains the excipient Phenylalanine and requires a documented restriction for patients diagnosed with the metabolic condition Phenylketonuria (PKU). Official regulatory documents do not specify or describe any classical drug-drug interactions involving major metabolic enzymes, such as the Cytochrome P450 (CYP) system, or drug transporters. The regulatory structure emphasizes constraints based on formulation excipients and conditions that limit the drug's action.

Retacrit (epoetin alfa-epbx) is an erythropoiesis-stimulating agent (ESA) that functions by mimicking the action of endogenous erythropoietin (EPO). Its mechanism centers on targeted humoral signaling and molecular cascades to govern red blood cell production. Retacrit acts as an agonist, directly binding to and activating the Erythropoietin Receptor (EPOR) found primarily on erythroid progenitor cells within the bone marrow. This binding event triggers an intracellular signaling cascade involving the Janus Kinase 2 (JAK2) and STAT5 pathways. The resultant phosphorylation and nuclear translocation of STAT5 proteins modulate gene expression to promote the survival and proliferation of these progenitor cells. This activity drives the maturation of red blood cell precursors by inhibiting apoptosis (programmed cell death). The continued differentiation and proliferation of these precursors lead to the eventual release of functional erythrocytes, shaping the final physiological output of the hematopoietic system.

How to Use Retacrit: Administration Guidelines

The usage of Retacrit (epoetin alfa-epbx) is governed by specific instructions concerning administration route, dosage, and treatment scheduling. The guiding principle across all approved uses is to administer the lowest effective dose to reduce the need for red blood cell transfusions, while maintaining the required management of the patient's iron status.

Administration Scope

Use Protocol

Treatment follows a two-stage process: an initial Correction Phase to achieve a defined target hemoglobin level, followed by an individualized Maintenance Phase. This procedural structure involves first the assessment of iron status, then specifying the starting dose and route of administration based on the patient’s condition. This is followed by a regimen of dose adjustments, which are limited to occur at intervals of at least four weeks, ensuring a controlled, step-wise approach throughout the treatment course.

Research Evidence / Overview of Studies for Retacrit

Retacrit (epoetin alfa-epbx) is a biosimilar medicine, meaning its research base is founded on studies that support its high similarity to the original reference product, epoetin alfa, combined with the extensive body of research already established for that original drug. This approach, known as the Totality of Evidence, is how regulatory bodies evaluated the data for Retacrit across various clinical situations.

Biosimilarity and Research Structure for Anemia in Chronic Kidney Disease

Studies exploring the use of Retacrit in adult patients with Chronic Kidney Disease (CKD) anemia primarily involve randomized controlled trials (RCTs). These RCTs often used non-inferiority designs, where researchers compared Retacrit to the original epoetin alfa medicine. This was done to explore whether there were no meaningful differences in how the body processes the medication or in the patterns observed in the body's response.

The primary outcomes examined in these trials focused on key blood markers, including the measurement of hemoglobin (Hb) levels and their stability over defined observation periods. Research also monitored the required epoetin dose associated with specific Hb level patterns, which allowed for a direct comparison between the biosimilar and the reference product. These findings describe patterns observed in the studies over intermediate-term treatment, describing patterns of similarity in how the two medicines relate to blood markers.

Evidence for Anemia Associated with Cancer Chemotherapy

Research for Retacrit in anemia associated with cancer chemotherapy was evaluated in studies that drew upon the foundational RCTs and meta-analyses conducted for the original epoetin alfa medicine. The evidence structure involves analytical and clinical data used to support the biosimilar finding, along with studies that specifically monitored the incidence of Red Blood Cell (RBC) transfusion.

Research for Transfusion Reduction in Surgery and HIV-Related Anemia

Research exploring patterns of donor blood transfusion requirements in specific surgical settings and in anemia associated with Zidovudine (AZT) use in HIV infection also relies on the Totality of Evidence approach.

• For Surgery: Studies explored the use of the medicine in patients scheduled for elective, noncardiac, nonvascular surgery who had a risk of major blood loss. The results apply only to the populations studied, and the research does not include studies examining its use for patients requiring immediate, acute correction of severe anemia.

• Evidence Gaps: Evidence is limited regarding the medicine's impact on patient-reported outcomes such as quality of life or fatigue. Research has not identified a specific optimal hemoglobin target level that was observed to relate to better outcomes than conservative management.

Common questions about Retacrit (FAQ)

Q: What is Retacrit and what does it do?

A: Retacrit is a biosimilar medicine containing the active substance epoetin zeta. It works in a similar way to the natural hormone erythropoietin and helps stimulate the production of red blood cells by the bone marrow. According to official product information, it is used to treat symptomatic anemia (low red blood cell count causing symptoms) caused by conditions such as chronic kidney failure.

Q: Can Retacrit be used to treat anemia in people with chronic kidney failure?

A: Yes, regulatory documents state that Retacrit is approved for treating anemia associated with chronic renal failure (long-term kidney failure). This use applies to patients both on and not yet on dialysis. It is used to help raise and maintain the red blood cell count to manage symptoms of anemia, as indicated by the prescribing physician.

Q: Is Retacrit approved for use in cancer patients receiving chemotherapy?

A: Official information indicates that Retacrit can be used to treat anemia in adult cancer patients who have non-myeloid malignancies (cancers that do not originate in the bone marrow). This treatment is specifically for patients receiving chemotherapy that can cause anemia. The therapy aims to reduce the need for red blood cell transfusions.

Q: Can Retacrit be used to increase blood before surgery (autologous blood donation)?

A: According to the official product information, Retacrit is approved for use in adults who are in a pre-donation program to collect their own blood before major surgery. It is administered to patients with moderate anemia who are scheduled for significant surgery and participating in a program for autologous blood donation.

Q: How is Retacrit given to a patient?

A: Retacrit is given by injection. Regulatory documents indicate it can be administered either intravenously (into a vein) or subcutaneously (under the skin). The specific route is determined by the treating physician based on the patient's condition, the underlying cause of anemia, and the treatment setting.

Official Storage and Disposal Instructions

Retacrit (epoetin alfa-epbx) must be stored in the refrigerator at a temperature between 2 C and 8 C (36 F and 46 F). To ensure product integrity, the drug must be kept in its original carton to protect it from light and must never be frozen or shaken.

All used syringes and needles must be immediately placed in a puncture-proof sharps disposal container with a tightly secured lid. Do not throw used needles, syringes, or medicine into household trash. Retacrit and all disposal materials must be kept out of the reach of children.